Walden Group Healthcare M&A Blog

Abbott is buying St.Jude Medical Further Consolidating the Medical Device Sector

05/05/2016
Abbott Laboratories (NYSE:ABT), a $20.4b maker of diagnostics, medical devices, pharmaceuticals and nutritionals, has agreed to buy St. Jude Medical Inc. (NASDAQ:STJ), a major maker of devices for cardiac rhythm management, cardiovascular, and atrial fibrillation. St. Jude Medical's strong positions in heart failure devices, atrial fibrillation...
Read More
What to Expect for 2016 Healthcare M&A Activity

01/24/2016
Recent volatility in worldwide markets, weakness in China, terrorism, softness in Europe and emerging markets, budget issues, and healthcare reform dislocations are among the dynamics that have clouded the 2016 picture for healthcare M&A. Here, we help clarfty things. China China is moving from a manufacturing and investment orientation to a...
Read More
Walden Advises Halma plc (LSE:HLMA) in its acquisition of Visiometrics, S.L. (Barcelona, Spain)

12/19/2015
The Walden Group is pleased to announce that it has advised Halma plc, a UK-based public company, in its acquisition of Visiometrics, S.L., located outside Barcelona, Spain. On Halma's behalf, The Walden Group identified Visiometrics as a strategic fit, cultivated a relationship with Visiometrics' principals, advised Halma on the transaction, and...
Read More
Medtronic's 2015 Deal Appetite Whetted By Tax Savings

10/27/2015
Medtronic's most recent acquistion target was Lazarus Effect, a maker of stroke diagnostic devices. After obtaining European approval, Lazarus Effect is working to get U.S. approval for the ReCover brain blot clot removal device, which works with Medtronic 's Solitaire stent that can be deployed in the brain to scoop out vessel-blocking clots that...
Read More
VasSol Ushers in a New Stroke Diagnostic Standard of Care

10/07/2015
The Journal of the American Medical Association - Neurology (JAMA Neurology) has indicated it will publish the results of the landmark stroke diagnostic study - VERiTAS (Vertebrobasilar Flow Evaluation and Risk of Transient Ischaemic Attack and Stroke study (VERiTAS). Acceptance by this highly prestigious and influential peer-reviewed journal...
Read More